IL1B and type 2 diabetes mellitus: For instance, trials have shown that blocking IL-1 signaling by recombinant IL-1 receptor antagonist Anakinra22 or neutralizing IL-1β through monoclonal antibodies Canakinumab24, Gevokizumab25 and LY218910226 result in an improvement in glycemic control in T2D patients27.